18F-deoxyglucose (FDG) PET-CMD
Last updated on April 2022Recruitment
- Recruitment Status
- Unknown status
- Estimated Enrollment
- 25
Inclusion Criteria
- Affiliated to a social insurance
- DCM diagnosed for more than two weeks without new ventricular arrhythmias or AuriculoVentricular Block (AVB) second or third degree , who responded to the usual treatment in the first two weeks of treatment
- Patients with DCM as defined by the European Society of Cardiology and recognized as such by the clinician cardiologist
- ...
- Affiliated to a social insurance
- DCM diagnosed for more than two weeks without new ventricular arrhythmias or AuriculoVentricular Block (AVB) second or third degree , who responded to the usual treatment in the first two weeks of treatment
- Patients with DCM as defined by the European Society of Cardiology and recognized as such by the clinician cardiologist
- Absence of other causes of non-family DCM discovered during the initial etiological ( some deficiency , toxic alcoholic or drug )
- Patients who underwent cardiac MRI for etiological DCM for less than four weeks at the time of obtaining consent
- Patients who have read and understood the information letter and who signed the consent form
- Lake of clinical or biological cases for periphiral myopathy or myotonia
- Patients above 18 years of age
- No family history of DCM
Exclusion Criteria
- No affiliation to a social insurance
- History of chemotherapy with anthracyclines
- Eosinophilia or immuno- allergic mechanism suspected
- ...
- No affiliation to a social insurance
- History of chemotherapy with anthracyclines
- Eosinophilia or immuno- allergic mechanism suspected
- History of severe thrombocytopenia type II ( heparin induced thrombocytopenia or immuno- allergic thrombocytopenia ) , heparin or unfractionated heparin , low molecular weight
- Patients with chronic liver disease
- Patients with active tuberculosis
- Ischemic cardiomyopathy defined by history of myocardial infarction or myocardial revascularization , stenosis ≥ 75% of the core or the left coronary artery anterior interventricular proximal stenosis ≥ 75% on at least two epicardial vessels
- Patients with connective : rheumatoid arthritis , systemic lupus erythematosus , systemic sclerosis , dermato- polymyositis , mixed connective
- Patients with Crohn's disease
- Family history of DCM
- Treatment immunosuppressive received from cardiac MRI
- Patient with signs of circulatory failure or congestive heart failure requiring intravenous positive inotropic therapy or diuretic therapy
- Major Trust
- Hypersensitivity to heparin.
- Other causes of non-family DCM discovered during the initial etiological ( some deficiency , toxic alcohol or medication , endocrine )
- History of acute myocarditis
- Minors
- History of sarcoidosis
- Patients with active neoplasia
- Pregnant or lactating women
- Significant organic valvular echocardiography
Summary
- Conditions
- Patients With Idiopathic Dilated Cardiomyopathy
- Type
- Interventional
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Affiliated to a social insurance
- DCM diagnosed for more than two weeks without new ventricular arrhythmias or AuriculoVentricular Block (AVB) second or third degree , who responded to the usual treatment in the first two weeks of treatment
- Patients with DCM as defined by the European Society of Cardiology and recognized as such by the clinician cardiologist
- ...
- Affiliated to a social insurance
- DCM diagnosed for more than two weeks without new ventricular arrhythmias or AuriculoVentricular Block (AVB) second or third degree , who responded to the usual treatment in the first two weeks of treatment
- Patients with DCM as defined by the European Society of Cardiology and recognized as such by the clinician cardiologist
- Absence of other causes of non-family DCM discovered during the initial etiological ( some deficiency , toxic alcoholic or drug )
- Patients who underwent cardiac MRI for etiological DCM for less than four weeks at the time of obtaining consent
- Patients who have read and understood the information letter and who signed the consent form
- Lake of clinical or biological cases for periphiral myopathy or myotonia
- Patients above 18 years of age
- No family history of DCM
Exclusion Criteria
- No affiliation to a social insurance
- History of chemotherapy with anthracyclines
- Eosinophilia or immuno- allergic mechanism suspected
- ...
- No affiliation to a social insurance
- History of chemotherapy with anthracyclines
- Eosinophilia or immuno- allergic mechanism suspected
- History of severe thrombocytopenia type II ( heparin induced thrombocytopenia or immuno- allergic thrombocytopenia ) , heparin or unfractionated heparin , low molecular weight
- Patients with chronic liver disease
- Patients with active tuberculosis
- Ischemic cardiomyopathy defined by history of myocardial infarction or myocardial revascularization , stenosis ≥ 75% of the core or the left coronary artery anterior interventricular proximal stenosis ≥ 75% on at least two epicardial vessels
- Patients with connective : rheumatoid arthritis , systemic lupus erythematosus , systemic sclerosis , dermato- polymyositis , mixed connective
- Patients with Crohn's disease
- Family history of DCM
- Treatment immunosuppressive received from cardiac MRI
- Patient with signs of circulatory failure or congestive heart failure requiring intravenous positive inotropic therapy or diuretic therapy
- Major Trust
- Hypersensitivity to heparin.
- Other causes of non-family DCM discovered during the initial etiological ( some deficiency , toxic alcohol or medication , endocrine )
- History of acute myocarditis
- Minors
- History of sarcoidosis
- Patients with active neoplasia
- Pregnant or lactating women
- Significant organic valvular echocardiography
Tracking Information
- NCT #
- NCT02078141
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Nicolas Piriou, MD Nantes UH
- Nicolas Piriou, MD Nantes UH